BlackRock
ETON icon

BlackRock’s Eton Pharmaceutcials ETON Stock Holding History

BlackRock’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.4M Sell
1,717,286
-21,621
-1% -$378K ﹤0.01% 2615
2025
Q4 		$29.4M Buy
1,738,907
+34,546
+2% +$608K ﹤0.01% 2857
2025
Q3 		$37M Buy
1,704,361
+172,650
+11% +$2.87M ﹤0.01% 2696
2025
Q2 		$21.8M Buy
1,531,711
+1,186,351
+344% +$18.8M ﹤0.01% 2968
2025
Q1 		$4.48M Buy
345,360
+27,735
+9% +$419K ﹤0.01% 3687
2024
Q4 		$4.23M Buy
317,625
+32,770
+12% +$332K ﹤0.01% 3793
2024
Q3 		$1.71M Buy
284,855
+2,466
+0.9% +$10.4K ﹤0.01% 4043
2024
Q2 		$929K Sell
282,389
-563
-0.2% -$1.97K ﹤0.01% 4199
2024
Q1 		$1.06M Sell
282,952
-1,289
-0.5% -$5.63K ﹤0.01% 4185
2023
Q4 		$1.24M Sell
284,241
-935
-0.3% -$3.75K ﹤0.01% 4191
2023
Q3 		$1.19M Sell
285,176
-13,049
-4% -$50.4K ﹤0.01% 4194
2023
Q2 		$1.04M Buy
298,225
+5,560
+2% +$20.4K ﹤0.01% 4285
2023
Q1 		$1.13M Buy
292,665
+1,914
+0.7% +$6.98K ﹤0.01% 4298
2022
Q4 		$820K Buy
290,751
+590
+0.2% +$1.59K ﹤0.01% 4465
2022
Q3 		$610K Sell
290,161
-1,552
-0.5% -$3.87K ﹤0.01% 4662
2022
Q2 		$764K Sell
291,713
-4,826
-2% -$16.2K ﹤0.01% 4644
2022
Q1 		$1.29M Sell
296,539
-2,403
-0.8% -$9.45K ﹤0.01% 4578
2021
Q4 		$1.28M Sell
298,942
-1,955
-0.6% -$9.35K ﹤0.01% 4575
2021
Q3 		$1.52M Sell
300,897
-161
-0.1% -$837 ﹤0.01% 4432
2021
Q2 		$1.85M Sell
301,058
-785,208
-72% -$5.82M ﹤0.01% 4305
2021
Q1 		$7.95M Buy
1,086,266
+33,321
+3% +$284K ﹤0.01% 3700
2020
Q4 		$8.56M Buy
1,052,945
+59,350
+6% +$458K ﹤0.01% 3448
2020
Q3 		$7.85M Buy
993,595
+292,175
+42% +$1.99M ﹤0.01% 3363
2020
Q2 		$3.82M Buy
701,420
+628,047
+856% +$3.12M ﹤0.01% 3630
2020
Q1 		$301K Sell
73,373
-437
-0.6% -$2.55K ﹤0.01% 4154
2019
Q4 		$532K Buy
73,810
+36,874
+100% +$228K ﹤0.01% 4146
2019
Q3 		$233K Buy
36,936
+10,844
+42% +$69.2K ﹤0.01% 4307
2019
Q2 		$206K Buy
26,092
+16,813
+181% +$131K ﹤0.01% 4363
2019
Q1 		$75K Sell
9,279
-630
-6% -$4.38K ﹤0.01% 4419
2018
Q4 		$60K Buy
+9,909
New +$60.8K ﹤0.01% 4448

Other funds holding ETON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return

BlackRock's ETON Position: Q1 2026 in Review

BlackRock reduced its Eton Pharmaceutcials (ETON) stake by 1.2% in Q1 2026, selling an estimated $378K and leaving 1,717,286 shares worth $42.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2615.

BlackRock first reported a position in ETON in Q4 2018 and has held it in 30 quarters since. 116 funds tracked by Wall St. Rank hold ETON as of Q1 2026.

  • BlackRock held 1,717,286 shares of Eton Pharmaceutcials worth $42.4M as of Q1 2026.
  • BlackRock sold 21,621 Eton Pharmaceutcials shares in Q1 2026, an estimated $378K.
  • Eton Pharmaceutcials made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2615 holding.
  • BlackRock first reported a position in Eton Pharmaceutcials in Q4 2018 and has held it in 30 quarters since.
  • 116 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.